Polyspecific Antibodies in Lymphoproliferative T-cell Disorders
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a 2-part study consisting of a Part 1, dose escalation and dose-finding component to establish the Maximal Tolerated Dose (MTD), or Recommended Part 2 Dose (RP2D) of LIS1 as a single agent; followed by a Part 2, to investigate anti-tumors efficacy of LIS1 in selected subtypes of Peripheral TCell Lymphoma (PTCL) and to further evaluate its safety and tolerability at RP2D.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Diagnoza zaawansowanego chłoniaka z komórek T (PTCL), który nie odpowiada lub powrócił po wcześniejszym leczeniu
- •Wcześniejsze leczenie co najmniej jednym schematem chemioterapii
- •Widoczne zmiany choroby w badaniach obrazowych
- •Wyzdrowiał z działań niepożądanych poprzedniego leczenia
- •Dostępne próbki tkanki do badań patologicznych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (8)
CHU de Caen
Caen, France
CHU de Clermont-Ferrand
Clermont-Ferrand, France
CHU Henri-Mondor
Créteil, France
CHU de Bordeaux - GH Sud - Hôpital Haut-Lévêque
Pessac, France
CHU de Lyon - Hôpital Lyon Sud
Pierre-Bénite, France
SC Ematologia Istituto Nazionale dei TumoriIRCCS Fondazione "G. Pascale"
Naples, Italy
IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola
Bologna, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
Trial contact
Françoise SHNEIKER, MD
Alain BALEYDIER
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/21/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.